Advanced Search

Journal of Traditional Chinese Medicine >

2022 , Vol. 42 >Issue 5: 773 - 780

DOI: https://doi.org/10.19852/j.cnki.jtcm.2022.05.009

Research Articles

Protective effects and mechanisms of Lizhong decoction (理中汤) against non-alcoholic fatty liver disease in a rat model

  • Jiayao YANG ,
  • Dongqing TAO ,
  • Wei MA ,
  • Song LIU ,
  • Yan LIAO ,
  • Lei SHU ,
  • Shu ZHANG ,
  • Chenyu LI ,
  • Nianlong DU
Expand
  • 1 Department of Gastroenterology, Wuhan Integrated TCM and Western Medicine Hospital, Wuhan 430022, China
    2 Department of Endocrinology, The Third People's Hospital of Hubei Province, Wuhan 430033, China
    3 Department of Center Laboratory, Wuhan Integrated TCM and Western Medicine Hospital, Wuhan 430022, China
    4 Hubei University of Traditional Chinese Medicine, Wuhan 430065, China
Dr. MA Wei, Department of Center Laboratory, Wuhan Integrated TCM and Western Medicine Hospital, Wuhan 430022, China. saturn119@126.com Telephone: +86-27-85332952
Dr. YANG Jiayao, Department of Gastroenterology, Wuhan Integrated TCM and Western Medicine Hospital, Wuhan 430022, China. yjy0813m@sina.com;

Received date: 2020-09-11

  Accepted date: 2020-11-22

  Online published: 2022-09-02

Supported by

Backbone Talents for TCM Clinical Characteristic Technology Inheritance Foundation of State Administration of Traditional Chinese Medicine: Protective Effects and Mechanisms of Lizhong Decoction Against Non-Alcoholic Fatty Liver Disease in a Rat Model[National Education Letter of Traditional Chinese Medicine (2018) No. 224]

Fold

Abstract

OBJECTIVE: To investigate the protective effects and molecular mechanisms of Lizhong decoction (理中汤, LZD) against non-alcoholic fatty liver disease (NAFLD).

METHODS: Male Wistar rats were fed a high-fat diet for four weeks to induce NAFLD, and were administered LZD by gavage for four weeks. Potential therapeutic targets for NAFLD were analyzed using network pharmacology. Liver pathology was evaluated using Oil Red O and hematoxylin-eosin staining. Furthermore, mitochondrial function, lipid metabolism, oxidative stress, and inflammatory response were examined.

RESULTS: Rats with NAFLD exhibited high levels of hepatic damage and cholesterol deposition. Moreover, apoptosis was increased, superoxide dismutase and glutathione content were reduced, malondialdehyde content was increased, and the protein expression of inflammatory cytokines and p-c-Jun N-terminal kinase was increased. The LZD treatment ameliorated mitochondrial dysfunction, reduced liver damage, inhibited oxidative stress and inflammatory response, upregulated peroxisome proliferator-activated receptor (PPAR)-γ expression, and suppressed dipeptidyl peptidase 4 (DPP4) expression in the liver.

CONCLUSION: It was found that LZD alleviates NAFLD by activating PPAR-γ and inhibiting DPP4.

Key words： non-alcoholic fatty liver disease; PPAR gamma; dipeptidyl peptidase 4; Lizhong decoction

Cite this article

Jiayao YANG , Dongqing TAO , Wei MA , Song LIU , Yan LIAO , Lei SHU , Shu ZHANG , Chenyu LI , Nianlong DU . Protective effects and mechanisms of Lizhong decoction (理中汤) against non-alcoholic fatty liver disease in a rat model[J]. Journal of Traditional Chinese Medicine, 2022 , 42(5) : 773 -780 . DOI: 10.19852/j.cnki.jtcm.2022.05.009

References

1. Hassan K, Bhalla V, EI Regal ME, A-Kader HH. Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol 2014; 20: 12082-101.
2. Koppe SW. Obesity and the liver: nonalcoholic fatty liver disease. Transl Res 2014; 164: 312-22.
3. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10: 656-65.
4. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012; 56: 1384-91.
5. Mavrogiannaki AN, Migdalis IN. Nonalcoholic fatty liver disease, diabetes mellitus and cardiovascular disease: newer data. Int J Endocrinol 2013; 2013: 450639.
6. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 2016; 65: 1038-48.
7. Marzuillo P, Grandone A, Perrone L, Miraglia Del Giudice E. Understanding the pathophysiological mechanisms in the pediatric non-alcoholic fatty liver disease: the role of genetics. World J Hepatol 2015; 7: 1439-43.
8. Enjoji M, Yasutake K, Kohjima M, Nakamuta M. Nutrition and nonalcoholic fatty liver disease: the significance of cholesterol. Int J Hepatol 2012; 2012: 925807.
9. Jin SH, Yang L, Fan XF, et al. Effect of divergence in residual feed intake on expression of lipid metabolism-related genes in the liver of meat-type ducks1. J Anim Sci 2019; 97: 3947-57.
10. Xuan GS, Oh SW, Choi EY. Development of an electrochemical immunosensor for alanine aminotransferase. Biosens Bioelectron 2003; 19: 365-71.
11. Zhou Y, Ding YL, Zhang JL, Zhang P, Wang JQ, Li ZH. Alpinetin improved high fat diet-induced non-alcoholic fatty liver disease (NAFLD) through improving oxidative stress, inflammatory response and lipid metabolism. Biomed Pharmacother 2018; 97: 1397-408.
12. Ong SB, Hall AR, Hausenloy DJ. Mitochondrial dynamics in cardiovascular health and disease. Antioxid Redox Signal 2013; 19: 400-14.
13. Pomara C, Neri M, Bello S, Fiore C, Riezzo I, Turillazzi E. Neurotoxicity by synthetic androgen steroids: oxidative stress, apoptosis, and neuropathology: a review. Curr Neuropharmacol 2015; 13: 132-45.
14. Tahara A, Kurosaki E, Yokono M, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 2013; 715: 246-55.
15. Mario M, Valerio R, Marcello D, et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease. Oxid Med Cell Longev 2018; 2018: 9547613.
16. Cheng S, Yang Y, Zhou Y, Xiang W, Yao H, Ma L. Influence of different concentrations of uric acid on oxidative stress in steatosis hepatocytes. Exp Ther Med 2018; 15: 3659-65.
17. Deevska G, Sunkara M, Karakashian C, Peppers B, Morris AJ, Nikolova-Karakashian MN. Effect of Procysteine on aging-associated changes in hepatic GSH and SMase: evidence for transcriptional regulation of smpd3. J Lipid Res 2014; 55: 2041-52.
18. Xu T, Zhou J, Zhu J, et al. Carnosic acid protects non-alcoholic fatty liver-induced dopaminergic neuron injury in rats. Metab Brain Dis 2017; 32: 483-91.
19. Duarte N, Coelho IC, Patarrão RS, Almeida JI, Penha-Gonçalves C, Macedo MP. How inflammation impinges on NAFLD: a role for kupffer cells. BioMed Res Int 2015; 2015: 984578.
20. Liberal R, Grant CR, Mieli-Vergani G, Vergani D. Autoimmune hepatitis: a comprehensive review. J Autoimmun 2013; 41: 126-39.
21. Malhi H, Brook SF, Werneburg NW, Gores GJ. Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis. J Biol Chem 2006; 281: 12093-101.
22. Celinski K, Dworzanski T, Fornal R, et al. Comparison of anti-inflammatory properties of peroxisome proliferator-activated receptor gamma agonists rosiglitazone and troglitazone in prophylactic treatment of experimental colitis. J Physiol Pharmacol 2013; 64: 587-95.
23. Baumeier C, Schlüter L, Saussenthaler S, et al. Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease. Mol Metab 2017; 6: 1254-63.
Options
Outlines

/

〈 〉